Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 17/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 17/20 | 0.73 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30013292 | 0.84 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL750446 | 0.84 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL748097 | 0.84 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL748096 | 0.84 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL2788899 | 0.83 | SLC6A4 (0.98) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL750207 | 0.83 | SLC6A4 (0.98) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL748126 | 0.82 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL30014278 | 0.82 | SLC6A4 (0.84) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL24836226 | 0.80 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3TGFBR1HRH3 | |
| SCHEMBL30014697 | 0.79 | SLC6A2 (0.82) | SLC6A4SLC6A2SLC6A3TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2429296-B1 | 7-([1,2,4,]TRIAZOLO[1,5,-A]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF | ALBANY MOLECULAR RES INC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9604960-B2 | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9173879-B2 | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a ]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| US-9034899-B2 | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150126517-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2015-05-07 | — | — | US | disclosed |
| US-20140364441-A1 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2014-12-11 | — | — | US | disclosed |
| EP-2429293-B1 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8815894-B2 | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8802696-B2 | 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2429295-B1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RES INC (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2429296-A1 | 7-([1,2,4,]TRIAZOLO[1,5,-A]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF | Albany Molecular Research, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2429293-A1 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2429295-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | Albany Molecular Research, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132437-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292242-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292250-A1 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292243-A1 | 7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292250-A1 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF | UACA, SCN1A, NLN | SLC6A4 389/4885SLC6A2 264/4885SLC6A3 716/4885 |
| US-20100292242-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | NLN, HTR3B, HTR2C | SLC6A4 98/4885SLC6A2 64/4885SLC6A3 87/4885 |
| US-20140364441-A1 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF | UACA, SCN1A, NLN | SLC6A4 389/4885SLC6A2 264/4885SLC6A3 716/4885 |
| US-20100292243-A1 | 7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF | CIAPIN1, CLN6, SCN1A | SLC6A4 339/4885SLC6A2 210/4885SLC6A3 553/4885 |
| US-20150126517-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | NLN, HTR3B, HTR2C | SLC6A4 98/4885SLC6A2 64/4885SLC6A3 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.